BSE · 543499
Achyut Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4 Cr with net profit ₹1 Cr — a 13.8% net margin, versus 8.35% the period before.
Shareholding
As of 2026-06-30
- Promoter47.4%
- Public47.47%
- FII5.13%
3,174 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.57× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #64 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Achyut Healthcare Limited(this company) | ₹167 Cr | 692 | 4.76 | 0.9% | 2.5% |
AI analysis
AI-generated · google/gemini-2.5-flashAchyut Healthcare Limited is listed with a market capitalization of Rs 171 Cr. The company reported revenue of Rs 3.97 Cr and a net profit of Rs 0.5477 Cr for the fiscal year ending March 2025. Diluted EPS stood at Rs 0.02. The promoter holding as of June 2026 was 47.317%.
Positives
- +The company has a negligible debt-to-equity ratio of 0, indicating a strong financial position.
- +Return on Equity (ROE) is high at 90%, suggesting efficient use of shareholder funds.
- +The profit margin is significantly high at 250% for the latest period.
Negatives
- −The P/E ratio is 710, which is high.
- −Revenue declined from Rs 6.8633 Cr in March 2024 to Rs 3.9688 Cr in March 2025.
- −Return on Capital Employed (ROCE) is low at 1.1273%.
- −Promoter holding decreased from 66.1771% in September 2022 to 47.317% in June 2026.
- −The company is under Enhanced Surveillance Measure (ESM).
Financial performance
Achyut Healthcare Limited's revenue for the fiscal year ending March 2025 was Rs 3.9688 Cr. This marks a decrease from Rs 6.8633 Cr in March 2024. Net profit for March 2025 was Rs 0.5477 Cr, with corresponding diluted EPS of Rs 0.02. The company's highest revenue reported was Rs 6.8633 Cr in March 2024, and its lowest was Rs 0.2742579 Cr in March 2021.
Profitability & returns
The company recorded a profit margin of 250% for the latest available period. Return on equity (ROE) was 90%, while return on capital employed (ROCE) stood at 1.1273%. These figures are based on the fiscal year ending March 2025. The EPS for March 2025 was Rs 0.02.
Balance sheet
Achyut Healthcare Limited has a book value per share of Rs 1.45. The company's debt-to-equity ratio is 0, indicating no debt reported. These metrics provide insight into the company's financial structure and asset backing.
Ownership & pledges
As of June 2026, promoters held 47.317% of the company's shares. Public shareholding was 47.5539%, and institutions (FII) held 5.1291%. The number of shareholders was 3174. There were no promoter pledges reported for the latest period.
Regulatory & surveillance
Achyut Healthcare Limited is currently under ESM (Enhanced Surveillance Measure), specifically ESM Stage 1. This indicates that the stock is subject to additional monitoring by regulatory bodies.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.